普萘洛尔降低产程延长患者剖宫产率的疗效:一项随机对照试验
这项多中心双盲安慰剂对照随机试验纳入164例≥36周单胎产程延长患者,比较静脉注射普萘洛尔2 mg与安慰剂对剖宫产率的影响。普萘洛尔组剖宫产率57.1%,安慰剂组57.5%(RR 0.99,95%CI 0.76-1.29),差异无统计学意义。试验因无效性提前终止。
要点
- 产程延长患者静脉注射普萘洛尔2 mg未能降低剖宫产率(57.1% vs 57.5%,RR 0.99,95%CI 0.76-1.29)。
- 产后出血在普萘洛尔组数值更高但未达统计学显著(20% vs 10%,RR 2.02,95%CI 0.93-4.43)。
- 试验因中期分析显示无效而提前终止。
核心结论
- 在这项多中心双盲安慰剂对照随机试验中,产程延长患者接受普萘洛尔与安慰剂相比,剖宫产率无差异。
研究设计与样本
- 双盲安慰剂对照随机试验,在大型学术健康系统内的两家医院开展,纳入≥36周单胎且产程延长的患者。
- 产程延长定义:潜伏期延长(破膜并接受缩宫素输注下,宫口扩张小于6 cm持续8小时或以上)或活跃期延长(破膜并接受缩宫素输注下,宫口扩张6 cm或以上且2小时或以上宫口扩张变化小于1 cm)。
- 排除严重子痫前期、母体心率小于70次/分、母体血压小于90/50 mm Hg、哮喘、产程中需胰岛素治疗的糖尿病或β受体阻滞剂心脏禁忌者。
- 随机分配至普萘洛尔2 mg静脉注射组或安慰剂2 mL生理盐水静脉注射组,允许重复给药一次。
- 样本量估算:假定剖宫产率45%、α 0.05、80%把握度,每组需163例以检出剖宫产率绝对降低15%;计划中期分析后因无效性终止试验。
主要发现
- 2020年7月至2022年6月,349例符合条件并接洽,164例入组随机,普萘洛尔组84例,安慰剂组80例。
- 剖宫产率两组无差异:普萘洛尔组57.1% vs 安慰剂组57.5%(RR 0.99,95%CI 0.76-1.29)。
- 潜伏期延长亚组(n=123)与活跃期延长亚组(n=41)、初产妇(n=137)与经产妇(n=27)结果相似。
- 产后出血频率普萘洛尔组数值更高但未达统计学显著:普萘洛尔组20% vs 安慰剂组10%(RR 2.02,95%CI 0.93-4.43)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 试验因计划中期分析显示无效而提前终止。
- 产后出血在普萘洛尔组数值更高但未达统计学显著(RR 2.02,95%CI 0.93-4.43)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To evaluate the rates of cesarean delivery in patients with prolonged labor randomized to receive intravenous (IV) propranolol compared with placebo. METHODS: A double-blind, placebo-controlled, randomized trial was conducted at two hospitals within a large academic health system. Eligible patients were at 36 weeks or more with a singleton gestation and prolonged labor , defined as: 1) prolonged latent phase of labor (dilation less than 6 cm after 8 hours or more with ruptured membranes and receiving oxytocin infusion) or 2) prolonged active phase of labor (dilation 6 cm or greater and less than 1-cm cervical dilation change over 2 hours or more with ruptured membranes and receiving oxytocin infusion). Patients were excluded for severe preeclampsia, maternal heart rate less than 70 beats per minute, maternal blood pressure less than 90/50 mm Hg, asthma, diabetes requiring insulin during labor, or a cardiac contraindication to β-blockade. Patients were randomized to propranolol (2 mg IV) compared with placebo (2 mL normal saline IV), with one possible repeat dose. The primary outcome was cesarean delivery; secondary outcomes included labor duration, shoulder dystocia, and maternal and neonatal morbidity. With an estimated cesarean delivery rate of 45%, α 0.05, and 80% power, we required 163 patients per group to detect a 15% absolute reduction in cesarean delivery rate. A planned interim analysis was performed, and the trial was stopped for futility. RESULTS: From July 2020 to June 2022, 349 patients were eligible and approached; 164 were enrolled and randomized, with 84 in the propranolol group and 80 in the placebo group. The rate of cesarean delivery was not different between groups (57.1% propranolol vs 57.5% placebo, relative risk [RR] 0.99, 95% CI 0.76-1.29). Results were similar by subgroup of prolonged latent (n=123) and active (n=41) phases of labor and nulliparous (n=137) and multiparous (n=27) patients. Though not statistically significant, the frequency of postpartum hemorrhage was higher in the propranolol group (20% vs 10%, RR 2.02, 95% CI 0.93-4.43). CONCLUSION: In this multisite, double-blind, placebo-controlled randomized trial, there was no difference in cesarean delivery rate for patients who received propranolol compared with those who received placebo for management of prolonged labor. CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov , NCT04299438.
引用
- McCoy JA, Walheim L, McCabe MG, et al. Efficacy of Propranolol to Reduce Cesarean Delivery in Prolonged Labor: A Randomized Controlled Trial. Obstet Gynecol. 2023. PMID: 37290102. doi:10.1097/AOG.0000000000005232
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。